Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Esophageal Neoplasms × pembrolizumab × Clear all

Phase

Status

Recruiting 14 Completed 13 Terminated 12 Active not recruiting 10 Unknown 3 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 12 Melanoma 8 Triple Negative Breast Neoplasms 7 Breast Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Neoplasms 6 Multiple Myeloma 6 Head and Neck Neoplasms 6 Carcinoma, Transitional Cell 6 Pancreatic Neoplasms 5 Carcinoma, Renal Cell 5 Recurrence 3 Lung Neoplasms 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Stomach Neoplasms 2 Sarcoma 2 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Kidney Neoplasms 2 Hematologic Neoplasms 2 Glioblastoma 2 Brain Neoplasms 2 Subcutaneous panniculitis-like T-cell lymphoma 1 Spinocerebellar Degenerations 1 Sezary Syndrome 1 Sarcoma, Synovial 1 Sarcoma, Kaposi 1

Interventions

Radiotherapy 3 Paclitaxel 3 Fluorouracil 3 nimotuzumab 2 Taxes 2 S 1 (combination) 2 Radiation 2 Oxaliplatin 2 Nivolumab 2 Ferrosoferric Oxide 2 Cisplatin 2 Cetuximab 2 Carboplatin 2 pembrolizumab 1 entinostat 1 apatinib 1 Watchful Waiting 1 Trastuzumab 1 TH 302 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Radiotherapy, Intensity-Modulated 1 Polymerase Chain Reaction 1 Observation 1 Nimodipine 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Ipilimumab 1 Immunotherapy 1 Gene Expression Profiling 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03881111 2020-02-11

KEYNOTE-590

Merck Sharp & Dohme LLC

Phase 3 Withdrawn

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡